Sensyne Health Begins Trading on AIM

Aug.17 -- Paul Drayson, chief executive officer at Sensyne Health, discusses how his company uses artificial intelligence to analyze clinical data of patients, how it helps the pharmaceutical discovery process, how they could utilize blockchain, what excites investors about the technology, why this is the right time for them to IPO, and his concerns over Brexit. He speaks on "Bloomberg Daybreak: Europe."